Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"They will manipulate the price back up. They cannot do that until they first cover their shorts. See how that works?"...What silly logic. There is right now only $3.22 left on the down side but the upside is uncapped. IF the "shorts" believed that AXAL was the real deal they would have covered their shorts long ago & that is assuming the silly logic that the shorts are the "manipulators" rather than the most savvy & correct ADXS players.
"Such silly logic. The fact that there have been no known buyout offers for ADXS means that BPs don’t like the science?".... If any BP believed that AXAL was the real deal that would make millions if approved, ANY BP would buy out ADXS for what would be peanuts & make millions for their shareholders. The fact that ZERO BP have attempted a buy out of ADXS proves that is not "silly logic", but the truth.
"Can you name another cancer treatment in all the world that has such an endorsement from people that know about cancer and put their money where their mouth is?".... If that was true, ADXS would have been bought out at this collapsed share price for what to any BP is peanuts. Bottom line is still the same. AMGEN & other BP know that AXAL is a dud & will not obtain FDA or EU approval. That is why there are ZERO buy out attempts.
"If the market views ADXS as worthless, why do shorts need to manipulate the share price down for years to get it this low?'... The reason the shorts took so long is to slowly torture naïve & gullible ADXS shareholders who can never admit that AXAL is a dud that will never get FDA or EU approval. ADXS death by a thousand cuts.
Hornet, the bottom line is AMGEN knows that AXAL is a dud & will not get FDA or EU approval. That's why AMGEN has no interest in buying out ADXS.
Barrell, you should have asked no balls Lombardo your questions during the ADXS conference call.
Random people don't even know ADXS exists let alone know or care about an ADXS conference call. Only those that are following ADXS,almost all would be shareholders,not just "Random people" would want to ask no balls Lombardo questions. LOL.
Gantor, you believe that no ADXS retail shareholder has the right to ask questions in a conference call. I believe they have a perfect right to be question Lombardo. How absurd to think that any "Uncle Joe or Aunt Millie" would even know or care about ADXS & would not be on the conference call. ALL shareholders, not just the lame analyst who have been completely WRONG about ADXS have the right to ask questions & no balls Lombardo has the responsibility to answer them.
When you get in line to ask questions, they don't ask you what question you are going to ask. Lombardo knows that unlike the staged lame analyst questions, retail shareholders are going to ask the questions that Lombardo doesn't have the balls to answer.
tin, the important questions that needed to be asked were not asked because Lombardo didn't have the testicular fortitude to face retail shareholders questions so they shut out any retail shareholders that were in the line to ask questions. Only the lame analysts were permitted to question Lombardo with soft ball questions. I know this to be fact as I was in the line & never had the chance to ask the pertinent questions that were conspicuously not asked by the lame analysts.
"If ADXS were to say that the company is for sale at $8-10 the BP execs would be in a fistfight in ADXS's lobby".... LOL. What total nonsense. IF AMGEN offered $8 a share for ADXS now, it would be gladly accepted by all shareholders who would much rather own AMGEN rather than ADXS.
"I don't agree with this assessment. AXAL and DUAL have a very good chance of getting approved and having reasonable sales"... If that was the case than AMGEN, the BP that knows more about ADXS than any other BP would have bought out ADXS for what to AMGEN is peanuts. However AMGEN & other BP know that AXAL is a dud & that's why ZERO buy out offers for ADXS even for peanuts.
"if someone really wanted to buy the company outright now in a hostile takeover they could probably do it for $8-$10, but we haven't even seen any interest in that low of a offer"... The reason there has not been & will not be a buy out is that BP & especially AMGEN know that AXAL is a stone cold dud & will not get FDA or EU approval. That's the bottom line to this ADXS disaster, not manipulation, the shorts or the evil empire MMs.
Chicken sheet Tony Lombardo refused to take ANY question from retail investors. I was in the que but was shut out as there were no questions from any retail shareholders taken . Any others on this board in the que to ask question & got ignored & shut out?
"Caledonia sold and gave away 51% of the Blanket mine". That is not true. CMCL was THREATENED & FORCED by Mugabe to sell & give away 51% of Blanket & forced CMCL to finance the Zimbabwe owners 51%.
This should be monster good for CMCL as management should know the best opportunities in Zimbabwe by now. If they don't, then all CMCL management should resign & be replaced. Disappointing share price reaction so far to this very positive news. Could the 51% of the Blanket mine that was stolen from CMCL be returned to CMCL?
‘Trust Me,’ Said The Smiling Crocodile | ZimEye
By Jacob Ngarivhume| Emerson Mnangagwa is too modest. He opened his inaugural address by suggesting that he has no particularly unique qualification to be President. But surely he cannot have forgotten the pivotal role he played in keeping Robert Mugabe and his ZANU(PF) party in power for all of 37 years. He has had a long and distinguished political career.
As Minister of State Security in the 1980s, for example, he played a crucial role in forcing Joshua Nkomo into exile and crushing ZAPU during Operation Gukurahundi. Lost are the words to describe the terror and horror suffered by tens of thousands of innocent civilians who were tortured and butchered to make Zimbabwe a de facto one-party state and grant his ‘father, mentor, comrade-in-arms’, Robert Mugabe, sweeping autocratic powers.
But the Crocodile would want us to forget this past. So he smiles and beguilingly asks us to let bygones be bygones so that we all move forward together in unity and peace. In his retelling of events, words become twisted to take on new meanings. Accountability for genocide only ‘opens old wounds’; justice becomes ‘retribution’; truths are but ‘unfounded allegations’ to divide the nation; and four years of unmitigated terror is reduced to a ‘moment of madness’. In a reinvented narrative, the Unity Accord allows mass murder to become a ‘closed chapter’, perpetrators on ‘both sides’ were granted amnesty from prosecution and, hence, no one deserves compensation. But we now know his reptilian ways only too well. So we shall not be soothed or fooled into forgetfulness, silence, and acquiescence. On the contrary, we shall remain vigilant until the day that the story of every victim, whose blood soaked the soils of Matabeleland, is told. Nor shall we rest until those responsible for genocide and crimes against humanity are made known and held to account.
Mnangagwa protests his innocence. But if he had nothing to hide, why then did he urge Mugabe to suppress the Chihambakwe Commission’s report on the massacres? How can we move forward together in peace and unity before we have dealt with the violence and conflict of the past? How can we have reconciliation and healing unless the truth is revealed and justice is served? Truth and justice demand the releasing of the Chihambakwe report; inviting international forensic teams to investigate mass graves; granting survivors the right to give their loved ones dignified burials; providing compensation to survivors for their losses; bringing perpetrators to justice; and signing the Rome Statutes of the International Criminal Court. Therein lie the conditions for moving forward with reconciliation, healing, and building lasting peace.
With his hand on his heart, our new President pledged to serve all citizens regardless of their colour or political affiliation. This was a cynical promise from someone whose every past action speaks only of racial discrimination, intolerance, vengeance and violence. He made no apology for his party’s reign of terror to purge the opposition’s rural support base after 2000. White farms were targeted; 200,000 farm workers lost their jobs; thousands of opposition supporters were intimidated and beaten; hundreds were murdered. And who other than the cold-blooded Crocodile had the stomach to launch Operation Murambatsvina during a bitterly cold winter? What had the countless thousands who lost their homes and livelihoods done to deserve such as terrible fate? They had committed the crime of exercising their constitutional right to vote for the candidate of their choice.
But Mugabe greatest debt to his hatchet man was the campaign of terror to defeat the democratic will of the people – the very people Mnangagwa now claims to unite in peace. As head of JOC, Mnangagwa delayed the counting of votes that gave Tsvangirai election victory and masterminded ZANU-PF’s campaign of torture, rape, and murder during the run-off Presidential election of June 2008. Yet, as the world witnessed yet another crime against humanity, to its shame and disgrace, it did nothing. The EU turned a blind eye to the atrocities and a deaf ear to the cries of the victims of violence. They not only engaged with a dictator and a mafia regime in 2013, but they demanded that those they funded do likewise.
Kate Hoey, the British Labour MP who has campaigned for years to highlight oppression under the Mugabe regime, described Mnangagwa in a recent parliamentary debate as “probably the one person in Zimbabwe who inspires even greater terror than Mugabe.” In response, Boris Johnson, the British Foreign Secretary, said in the House of Commons, “Nobody wants simply to see the transition from one unelected tyrant to the next.” Why then the unseemly haste of Britain’s Africa Minister, Rory Stewart, to congratulate Mnangagwa and have the IMF embargo lifted? It is a reminder that Britain and the EU, for all their sanctimonious lecturing about the rule of law, human rights and democracy, are perfectly willing to sacrifice truth, justice, and the rights of victims for peace and stability under yet another tyrant.
And to fellow Zimbabweans yearning for peace, we understand your longings and the hopes you have put in our new President. But look closely into his eyes. For there you will see only Crocodile tears for you and his hapless victims. And though he may smile, his bite is deadly.
"Riiiiight, the fact that Amgen hasn’t bought ADXS out (yet)". The absurdity of "YET" shows incredible naïveté. So either Amgen believes AXAL is the real deal but Amgen is so smart that they know that the ADXS share price will decline to much lower levels so it could buy ADXS for less than peanuts or Amgen believes AXAL is the real deal but will wait until the share price is 10 times higher so they could pay a lot more for what they could have bought for much less. Terrific logic. LOL
"When ADXS brings AXAL to market in the EU in 12-15 months.." LOL. If that even had a chance of happening, Amgen would have bought out ADXS for what to Amgen, would be peanuts. However Amgen, who knows more about ADXS than ANY BP, knows that AXAL is a dud & will not get FDA or EU approval, let alone AXAL to market in the EU.
Zimbabwe's Mnangagwa gives key cabinet jobs to military figures
2 hours ago
Emmerson Mnangagwa has promised a "new democracy" for Zimbabwe
Zimbabwe's new President Emmerson Mnangagwa has named his cabinet, appointing senior military figures to high-profile positions.
Critics have said that it has dashed hopes of change in the country.
Mr Mnangagwa was inaugurated as president last week. He took over from Robert Mugabe who had been in power for 37 years.
Mr Mugabe stepped down after the army took control of the country, following a power struggle in the ruling party.
Thousands of people celebrated Mr Mugabe's resignation as they hoped the failed economy would improve.
Some had hoped that President Mnangagwa would appoint members of the opposition to his cabinet, to form a transitional government until elections next year but this did not happen.
What has been the reaction?
The appointments led government critic Tendai Biti to suggest that Zimbabweans were "wrong" to have hoped for change."Up until now, we had given the putsch the benefit of the doubt. We did so in the genuine, perhaps naive view that the country could actually move forward. We craved change, peace & stability in our country. How wrong we were," he said.
People remove, from the wall at the International Conference centre, where parliament had their sitting, the portrait of former Zimbabwean President Robert Mugabe after his resignation on November 21, 2017 in Harare.
Many Zimbabweans celebrated the ousting of Robert Mugabe
Wilf Mbanga, a Zimbabwean journalist who lives in exile in South Africa, told the BBC that the new minister of agriculture Perence Shiri "was not known for his love of democracy".
A minister who served in Mr Mugabe's government, Jonathan Moyo, said the changes meant that Zanu-PF, the party which has governed Zimbabwe since independence in 1980, was "dead" and the military was now in charge.
Newspaper owner Trevor Ncube said the cabinet was "very disappointing".
"Largely the same people that caused this crisis have been recycled. The honeymoon comes to an end and reality dawns. His concern seems to have been rewarding those who brought him to power and Zanu-PF unity," he said.
Who are the most controversial new cabinet members?
Sibusiso Moyo, the general who became the face of the recent military takeover, is the new foreign minister.
In his announcement, he was at pains to deny that the military takeover was a coup so some will criticise his promotion to the cabinet.
He holds a PhD in International Relations and at one point was the leader of the elite military unit, known as the "green berets squad".
The head of Zimbabwe's air force, Perence Shiri, was named the minister of agriculture and land affairs.
He is notorious for having led the military operation against those seen as opponents of Mr Mugabe in Matabeleland in the early 1980s.
The operation, led by the North-Korean trained Fifth Brigade of the army, resulted in the killing of an estimated 20,000 civilians.
As lands minister, he will presumably be in charge of Zimbabwe's controversial land reform programme.
This saw the seizure of thousands of farms owned by the white minority which had previously been in charge of the country. Critics say this wrecked Zimbabwe's once thriving economy and led millions of Zimbabweans to leave the country to find work.
Zimbabwe's Mugabe digs in heels as ruling party moves to depose him
HARARE (Reuters) - Zimbabwe’s President Robert Mugabe appeared in public on Friday for the first time since the army took charge, as the ruling party made plans to force him to step down after more than three decades in power.
The president, who is 93, opened a graduation ceremony at Zimbabwe Open University in Harare. He wore blue and yellow academic robes and a mortar board hat and appeared to fall asleep in his chair as his eyes closed and his head lolled.
Mugabe led the country’s liberation struggle and has dominated its politics since independence in 1980 but this week’s army takeover signals the collapse of his authority despite his insistence he remains in charge. A senior member of the ZANU-PF ruling party said it wanted him gone.
“If he becomes stubborn, we will arrange for him to be fired on Sunday,” the source said. “When that is done, it’s impeachment on Tuesday.”
In contrast, the military said in a statement on national television it was “engaging” with Mugabe. It referred to him as Commander in Chief and said it would announce an outcome as soon as possible.
The ruling ZANU-PF party has called for a mass meeting in the capital on Saturday to show its support for the War Veterans group in their bid to remove Mugabe.
Mugabe is revered as an elder statesman and independence leader but he is also viewed by many in Africa as a president who crippled his country by remaining in power too long. He calls himself the grand old man of African politics.
The army appears to want him to go quietly and allow a transition to Emmerson Mnangagwa, whose sacking last week as vice president triggered the takeover.
A goal of the generals is to prevent Mugabe handing power to his wife, Grace, who appeared on the cusp of power after Mnangagwa was pushed out.
“NO GOING BACK”
Zimbabwe’s official newspaper, the Herald, ran photographs late on Thursday showing Mugabe grinning and shaking hands with military chief General Constantino Chiwenga, who seized power this week.
The images stunned Zimbabweans who said it meant Mugabe was managing to hold out against Chiwenga’s coup. Some political sources said he was trying to delay his departure until elections scheduled for next year.
The ZANU-PF source said that was not the case. Anxious to avoid a protracted stalemate, party leaders were drawing up plans to dismiss Mugabe at the weekend if he refused to quit, the source said.
“There is no going back,” the source told Reuters. “It’s like a match delayed by heavy rain, with the home side leading 90-0 in the 89th minute.”
The army is camped on his doorstep. Grace Mugabe is under house arrest and her key political allies are in military custody. The police, once a bastion of support, have showed no signs of resistance.
Furthermore, he has little popular backing in the capital, a stronghold of support for opposition parties that have tapped into the anger and frustration at his handling of the economy, which collapsed after the seizure of white-owned farms in 2000.
Unemployment is now running at nearly 90 percent and chronic shortages of hard currency have triggered hyperinflation, with the prices of imports rising as much as 50 percent a month.
Mugabe has won a series of elections but his critics in Africa and the West say his handling of the economy has been disastrous and he has used violence to maintain power. Botswana’s President Ian Khama told him to resign.
“I don’t think anyone should be President for that amount of time. We are Presidents. We are not monarchs. It’s just common sense,” Khama said.
Speaking at a Southern African Development Community meeting in Botswana’s capital Gaborone, South Africa’s President Jacob Zuma struck a different chord.
“We note with great concern the unfolding political development in Zimbabwe and we hope that they will not lead to unconstitutional change of government,” Zuma said.
“VERY STUBBORN”
Dumiso Dabengwa, a Zimbabwean liberation war veteran and KGB-trained former intelligence chief, said Mugabe’s fate was sealed but old age was causing him to dig in his heels.
“At his age, everybody becomes very stubborn and he would be no exception,” he told reporters in Johannesburg.
“He certainly will not do it easily, but I think the people will show him that he’s no longer wanted.”
U.S. Secretary of State Rex Tillerson on Friday urged “a quick return to civilian rule” in Zimbabwe.
Tillerson urges return to civilian rule in ZimbabweTillerson urges return to civilian rule in Zimbabwe
“Zimbabwe has an opportunity to set itself on a new path, one that must include democratic elections and respect for human rights,” Tillerson told the foreign ministers from the African continent ahead of a meeting in Washington.
The United States, a longtime Mugabe critic, is seeking “a new era”, the State Department’s top official for Africa said, an implicit call for Mugabe to quit.
In an interview with Reuters, acting U.S. Assistant Secretary of State for African Affairs Donald Yamamoto appeared to dismiss the idea of keeping Mugabe in an interim or ceremonial role.
“It’s a transition to a new era for Zimbabwe, that’s really what we’re hoping for,” Yamamoto said.
For its part, China’s Foreign Ministry called for a peaceful resolution in Zimbabwe under a legal framework.
"Well O'Connor got the last laugh".. O'Connor got the last laugh because as soon as he left, the ADXS share price collapsed & he was replaced by an incompetent bozo.
Cancer Treatment Update: Second Gene Therapy Receives Approval
Not a word about ADXS or AXAL in this revealing article.
Zacks Equity Research
ZacksOctober 20, 2017
"With the approval of Gilead Sciences, Inc.’s GILD Yescarta, this week saw the approval of the second CAR-T therapy for treating cancer. It is regarded as one of the most advanced immune-oncology treatment options.
Moreover, the FDA has granted priority review to label expansion applications for four major cancer drugs. These include AstraZeneca, plc’s AZN Lynparza for advanced breast cancer and Imfinzi for an earlier stage of lung cancer, Bristol-Myers Squibb Company’s BMY Opdivo for melanoma patients with high risk of recurrence and Exelixis, Inc.’s EXEL Cabometyx for advanced renal cell carcinoma (“RCC”).
Meanwhile, Ipsen along with its partner, Exelixis, announced positive results from a phase III study on its hepatocellular carcinoma candidate. Moreover, AbbVie ABBV entered into an immuno-oncology research collaboration with Harpoon Therapeutics, focused on novel T-cell recruiting biologic therapies. AbbVie will use Harpoon's tri-specific T-cell activating construct platform for developing its immuno-oncology pipeline.
Let’s see the news in details.
Key News
Gilead’s acquisition of Kite Pharma for nearly $12 billion has finally paid off with the approval of Yescarta (axicabtagene ciloleucel), the latter’s chimeric antigen receptor T-cell (CAR T) therapy candidate. The FDA approved the therapy for treating relapsed or refractory large B-cell lymphoma (r/rLBCL) in adults who have received two or more lines of systemic therapy.
The various forms of r/rLBCL for which Yescarta is approved include diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and high-grade B-cell lymphoma. This is the second gene therapy to be approved in the United States after Novartis AG’s NVS Kymriah, which received approval in August for acute lymphoblastic leukemia.
CAR-T therapy is the most advanced form of treating cancer. This is done by modifying the patient’s T-cell, part of the body’s immune system, to fight cancerous cells. The therapy is manufactured specifically for each single patient.
AstraZeneca and partner Merck’s MRK marketed advanced ovarian cancer drug, Lynparza, received priority review for its supplemental New Drug Application (sNDA) seeking approval in previously treated (chemotherapy) patients with HER2-negative metastatic breast cancer. The FDA is expected to give its decision in the first quarter of 2018. Lynparza is in different studies for a range of tumor types including breast, prostate and pancreatic cancers as well as earlier-line settings for ovarian cancer.
Meanwhile, the FDA has also granted priority review to AstraZeneca’s sNDA for key cancer drug, Imfinzi for unresectable non-small cell lung cancer. (Read more: AstraZeneca's sNDA for Two Cancer Drugs Gets Priority Review)
Bristol-Myers announced that the FDA has granted priority review to the supplemental Biologics License Application (sBLA) for the label expansion of Opdivo. The company is looking to get the drug approved for treating patients with melanoma, who are at high risk of disease recurrence following complete surgical resection.
The drug is already approved for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. Moreover, the company announced that Opdivo, alone or in combination with Yervoy, achieved encouraging results in previously treated small cell lung cancer patients in phase I/II CheckMate -032 study. The Opdivo monotherapy and combo-therapy achieved an objective response rate of 11% and 22%, respectively. (Read more: Bristol-Myers Gets Priority Review for Opdivo Label Expansion)
Other News
Exelixis’ renal carcinoma drug, Cabometyx, was also granted priority review by the FDA for its sNDA. The sNDA sought approval of Cabometyx for patients with treatment-naive advanced RCC. The FDA deemed the sNDA to be sufficiently complete with a decision expected on Feb 15, 2018. Moreover, the company’s advanced hepatocellular carcinoma candidate, cabozantinib, achieved statistically significant and clinically meaningful improvement in median overall survival rate over placebo in phase III CELESTIAL study. Exelixis is developing this candidate in partnership with Ipsen.
Meanwhile, Inovio Pharmaceuticals, Inc. INO initiated a phase Ib/II study, which will evaluate a combination of INO-5401, a T-cell activating immunotherapy and INO-9012, an immune activator with Roche’s anti-PDL1 inhibitor, Tecentriq, in advanced bladder cancer. Immune Design also initiated a pivotal phase III study to support a regulatory application for CMB305for treating patients with synovial sarcoma."
Cancer Treatment Update: Second Gene Therapy Receives Approval
Not a word about ADXS or AXAL in this revealing article.
Zacks Equity Research
ZacksOctober 20, 2017
"With the approval of Gilead Sciences, Inc.’s GILD Yescarta, this week saw the approval of the second CAR-T therapy for treating cancer. It is regarded as one of the most advanced immune-oncology treatment options.
Moreover, the FDA has granted priority review to label expansion applications for four major cancer drugs. These include AstraZeneca, plc’s AZN Lynparza for advanced breast cancer and Imfinzi for an earlier stage of lung cancer, Bristol-Myers Squibb Company’s BMY Opdivo for melanoma patients with high risk of recurrence and Exelixis, Inc.’s EXEL Cabometyx for advanced renal cell carcinoma (“RCC”).
Meanwhile, Ipsen along with its partner, Exelixis, announced positive results from a phase III study on its hepatocellular carcinoma candidate. Moreover, AbbVie ABBV entered into an immuno-oncology research collaboration with Harpoon Therapeutics, focused on novel T-cell recruiting biologic therapies. AbbVie will use Harpoon's tri-specific T-cell activating construct platform for developing its immuno-oncology pipeline.
Let’s see the news in details.
Key News
Gilead’s acquisition of Kite Pharma for nearly $12 billion has finally paid off with the approval of Yescarta (axicabtagene ciloleucel), the latter’s chimeric antigen receptor T-cell (CAR T) therapy candidate. The FDA approved the therapy for treating relapsed or refractory large B-cell lymphoma (r/rLBCL) in adults who have received two or more lines of systemic therapy.
The various forms of r/rLBCL for which Yescarta is approved include diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and high-grade B-cell lymphoma. This is the second gene therapy to be approved in the United States after Novartis AG’s NVS Kymriah, which received approval in August for acute lymphoblastic leukemia.
CAR-T therapy is the most advanced form of treating cancer. This is done by modifying the patient’s T-cell, part of the body’s immune system, to fight cancerous cells. The therapy is manufactured specifically for each single patient.
AstraZeneca and partner Merck’s MRK marketed advanced ovarian cancer drug, Lynparza, received priority review for its supplemental New Drug Application (sNDA) seeking approval in previously treated (chemotherapy) patients with HER2-negative metastatic breast cancer. The FDA is expected to give its decision in the first quarter of 2018. Lynparza is in different studies for a range of tumor types including breast, prostate and pancreatic cancers as well as earlier-line settings for ovarian cancer.
Meanwhile, the FDA has also granted priority review to AstraZeneca’s sNDA for key cancer drug, Imfinzi for unresectable non-small cell lung cancer. (Read more: AstraZeneca's sNDA for Two Cancer Drugs Gets Priority Review)
Bristol-Myers announced that the FDA has granted priority review to the supplemental Biologics License Application (sBLA) for the label expansion of Opdivo. The company is looking to get the drug approved for treating patients with melanoma, who are at high risk of disease recurrence following complete surgical resection.
The drug is already approved for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. Moreover, the company announced that Opdivo, alone or in combination with Yervoy, achieved encouraging results in previously treated small cell lung cancer patients in phase I/II CheckMate -032 study. The Opdivo monotherapy and combo-therapy achieved an objective response rate of 11% and 22%, respectively. (Read more: Bristol-Myers Gets Priority Review for Opdivo Label Expansion)
Other News
Exelixis’ renal carcinoma drug, Cabometyx, was also granted priority review by the FDA for its sNDA. The sNDA sought approval of Cabometyx for patients with treatment-naive advanced RCC. The FDA deemed the sNDA to be sufficiently complete with a decision expected on Feb 15, 2018. Moreover, the company’s advanced hepatocellular carcinoma candidate, cabozantinib, achieved statistically significant and clinically meaningful improvement in median overall survival rate over placebo in phase III CELESTIAL study. Exelixis is developing this candidate in partnership with Ipsen.
Meanwhile, Inovio Pharmaceuticals, Inc. INO initiated a phase Ib/II study, which will evaluate a combination of INO-5401, a T-cell activating immunotherapy and INO-9012, an immune activator with Roche’s anti-PDL1 inhibitor, Tecentriq, in advanced bladder cancer. Immune Design also initiated a pivotal phase III study to support a regulatory application for CMB305for treating patients with synovial sarcoma."
"The market cap does not determine a buyout price". LOL.
More hogwash as usual. If Amgen believed that AXAL is the real deal & will get FDA & EU approval, it would buy out ADXS now at this miniscule market cap & make millions off the drug. Amgen does NOT believe AXAL is the real deal that is why no Amgen buy out & is why the shorts refuse to cover & ZERO BP wants to buy out ADXS.
Why Amgen will NOT buy out ADXS. Amgen knows more about ADXS than any other BP. Amgen cherry picked ADXS - NEO because Amgen believes NEO could be the real deal. The reason Amgen won't buy out ADXS for what would be peanuts to Amgen, is because Amgen knows AXAL is a dud & it will not get FDA or EU approval. Same reason the shorts don't cover & NO BP is interested in buying out ADXS.
The all knowing ORACLE of gold & the stock market posted.... "YES!
There is another BIG correction coming soon and
gold will go to $5000+++"... Of course we all may be dead by then..LOL
The major problem with CMCL is incompetent management that is totally incapable of taking CMCL to the next growth level. When CEO Steve Curtis decided to list the stock on the NYSE AMEX & institute another reverse split this is the reason stated: "The board of directors of the Company believes that the listing of the Company's shares on NYSE MKT may result in increased trading liquidity and enable access to a larger pool of potential US investors". Of course that has not happened. Volume & liquidity on the AMEX & now even in Toronto are very low, taking into consideration the reverse split. CMCL is essentially a one trick pony that owns a minority interest, 49%, in one producing gold mine in Zimbabwe, possibly the most investor shunned country for gold mining because of the big time political & country risk. It had been thought that the real reason to list on the AMEX & do the reverse split was to take CMCL to the next growth phase by either merger or joint venture with economic producing gold properties OUTSIDE of the investor despised Zimbabwe. CMCL needs additional economic, producing gold properties outside Zimbabwe to reduce political & country risk & to take CMCL to the next level of growth. So far, there is absolutely no reason or advantage to CMCL shareholders for the AMEX listing & the reverse split. Incompetent management is CMCL's shareholders biggest obstacle to the future growth of the company & increasing share price. If not for the dividend, there is no reason for any new investors to bet on CMCL with it's incompetent management when there are so many more far superior junior gold stocks to choose from.
Amgen is only interested in ADXS NEO which they believe has has a good chance for sucess & that's why they bought it from ADXS. Amgen has no such belief in AXAL or they would buy out ADXS now for what would amount to peanuts to Amgen.
If Amgen,the BP that knows more about ADXS than any BP, believed that AXAL was the real deal, they would buy out ADXS now at this miniscule ADXS market cap. It's perfectly obvious that Amgen does NOT believe AXAL is the real deal & that's why NO Amgen buy out.
I never said the tutes determine FDA or EU approval. The tutes believe that AXAL won't get FDA or EU approval & that is why they are deserting the ADXS ship.
The tutes that funded ADXS are deserting the ADXS ship because they know AXAL won't get FDA or EU approval. If this was not true, they would be buying big time at this "supposed" undervalued share price.
The collapsed ADXS share price & market cap, the fact that shorts refuse to cover, & that zero BP wants to buy out ADXS tell the true story. They know AXAL is a dud & will not get FDA or EU approval.
"AXAL is a dud". Tell that to the patients it has helped. Let us know what they say"....Tell that to the shorts who refuse to cover at the "undervalued" low ADXS stock price & BP who want no part of buying out ADXS. Both know AXAL is a dud & will not get FDA or EU approval.
"If ADXS's phase 3 data is approvable, before actual approval, then why would ADXS be in a lower league than KITE, for example? Now substitute "if ADXS gets EMA approval..." IF,IF,IF,IF. Just a load of speculative IFs. The reason ADXS share price continues to get clobbered & NO buy out offers is that AXAL is a dud. The shorts know it & BP knows it. NO FDA or EU approval.
Premise 1: ADXS a young biotech that gets shorted and manipulated must have bad science - correct.
Premise 2:ADXS a young biotech that has not yet been bought out must have bad science - correct.
Premise 3: ADXS a young biotech with impressive trial data has good science - incorrect.
"There is massive collusion occurring with this manipulation. It is the only plausible explanation". That is not the only plausable explanation. The reason the ADXS shorts have massively shorted & refuse to cover & why NO BP wants to buy out ADXS is that the shorts & BP know that AXAL is a dud & will not get FDA or EU approval.
The tutes are abandoning the ADSX ship in droves. These former ADXS funders all must believe that AXAL is a dud & will not get FDA or EU approval or they wouldn't have sold out their entire ADXS position.
Pacific Gold is now Pacific Gold & Royalty Corp. Landau registered the company in Wyoming & is trying to resurrect the old PCFG scam. The stock is not trading yet......https://www.sec.gov/Archives/edgar/data/1137855/000151597117000137/pcfgform10092617.htm